Stealth’s Elamipretide Gets US FDA Panel Nod, But Not A Glowing Endorsement, For Barth Syndrome

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 that efficacy had been shown for the ultra-rare disease, but even panelists in the majority questioned whether the product satisfied the threshold requirement for an adequate and well-controlled study.